iXCells Biotechnologies (“iXCells”), a leading provider of human cell-based solutions and custom iPSC services, and Rosebud Biosciences, an innovator in organoid development and complex 3D biology, today announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases.
To continue reading click here
